MYOZ2

Chr 4AD

myozenin 2

Also known as: C4orf5, CMH16, CS-1, FATZ-2

MYOZ2 encodes myozenin-2, a sarcomeric protein that tethers calcineurin to alpha-actinin at the Z-line and modulates calcium-dependent signaling in cardiac and skeletal muscle. Mutations cause familial hypertrophic cardiomyopathy type 16 with autosomal dominant inheritance.

Summary from RefSeq, OMIM, UniProt
Research Assistant →

Primary Disease Associations & Inheritance

Cardiomyopathy, hypertrophic, 16MIM #613838
AD
UniProtCardiomyopathy, familial hypertrophic, 16
0
Active trials
4
Pubs (1 yr)
24
P/LP submissions
5%
P/LP missense
1.07
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryMYOZ2
🧬
Gene-Disease Validity (ClinGen)
hypertrophic cardiomyopathy · ADDisputed

Disputed — evidence questions this relationship

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
22 unique Pathogenic / Likely Pathogenic· 199 VUS of 343 total submissions
📖
GeneReview available — MYOZ2
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.07LOEUF
pLI 0.002
Z-score 1.41
OE 0.54 (0.301.07)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
0.54Z-score
OE missense 0.87 (0.751.01)
125 obs / 143.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.54 (0.301.07)
00.351.4
Missense OE0.87 (0.751.01)
00.61.4
Synonymous OE1.01
01.21.6
LoF obs/exp: 6 / 11.1Missense obs/exp: 125 / 143.2Syn Z: -0.07
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
limitedMYOZ2-related hypertrophic cardiomyopathyOTHERAD
DN
0.81top 10%
GOF
0.6932th %ile
LOF
0.2969th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

343 submitted variants in ClinVar

Classification Summary

Pathogenic20
Likely Pathogenic2
VUS199
Likely Benign83
Benign25
Conflicting12
20
Pathogenic
2
Likely Pathogenic
199
VUS
83
Likely Benign
25
Benign
12
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
20
0
20
Likely Pathogenic
0
1
1
0
2
VUS
9
155
35
0
199
Likely Benign
0
4
27
52
83
Benign
0
0
21
4
25
Conflicting
12
Total916010456341

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

MYOZ2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Key Publications
Landmark & review papers · by relevance
PubMed
Top 3 results · since 2015Search PubMed ↗